0001193125-26-208893
SEC filingQ1 delivered profitability with $358.4M operating income versus prior loss, driven by restructuring expense reductions, despite 1.9% revenue decline from ELEVIDYS demand changes post-safety events and label update.
Sarepta Therapeutics reported a transformative Q1 2026, achieving GAAP profitability across key metrics following strategic actions. Revenue of $730.8 million represented a 1.9% year-over-year decline from $744.9 million. This decrease was primarily driven by lower ELEVIDYS sales volume, reflecting changes in demand following the safety events that occurred in 2025 and subsequent label update for ELEVIDYS which included only the ambulatory patient population for treatment. These dynamics constrained product revenue growth but were offset by overall financial improvements.
Operating income marked a dramatic shift to $358.4 million profit from a -$300.4 million loss in Q1 2025, delivering a 219.3% improvement. This swing resulted from a July 2025 strategic restructuring plan designed to reduce operating expenses and align the cost structure with strategic priorities, aiming to enhance financial flexibility and meet 2027 financial obligations. The restructuring enabled significant expense reductions, igniting the profitability turnaround and providing a foundation for sustained operational efficiency.
Operating margin expanded to 49.0%, underscoring the effectiveness of cost discipline in converting revenue into profits despite topline pressures. Cash flow dynamics showed moderation in burn, with net cash used in operating activities at -$202.7 million, an improvement from -$583.4 million prior year. Capital expenditures dropped sharply to $2.1 million from $43.7 million, resulting in free cash flow of -$204.8 million. These trends reflect better working capital management and restrained investments, supporting liquidity amid restructuring.
Operationally, the company continues evaluating supply relationships for products like ELEVIDYS, considering production volume, logistics, and business continuity, with Aldevron as a key plasmid provider. Prior manufacturing cost expensing practices for pre-approval products have transitioned, with PMO product costs fully consumed by 2022. These elements position Sarepta to navigate ELEVIDYS challenges while leveraging restructuring benefits for future flexibility.